Downloads: 1
Review Paper | Pharmacy | Volume 15 Issue 6, June 2026 | Pages: 1112 - 1112 | India
A Review Article on the Bioavailability of Lumateperone
Abstract: Lumateperone is a recently approved second generation antipsychotic developed for the treatment of schizophrenia. Its pharmacological profile differs from conventional agents because it acts on serotonergic, dopaminergic, and glutamatergic pathways at the same time. The drug shows high affinity for 5 HT2A receptors, moderate affinity for D2 receptors, and low affinity for H1 and 5 HT2C receptors, which may contribute to its therapeutic effects and tolerability. Lumateperone functions as a presynaptic D2 partial agonist and postsynaptic D2 antagonist, helping regulate dopamine activity in brain regions associated with schizophrenia. It also enhances NMDA mediated glutamate signaling and modulates serotonin through serotonin transporter inhibition and 5 HT2A receptor blockade. The drug has an oral bioavailability of about 4.4 percent and reaches peak plasma concentration within one to two hours, while steady state levels are achieved after five days of repeated dosing. Extensive metabolism produces more than twenty metabolites, with elimination occurring mainly through urine. Its terminal half- life is approximately eighteen hours. The distinct mechanism of action and favorable pharmacokinetic profile make lumateperone a promising option for managing both positive and negative symptoms of schizophrenia.
Keywords: Lumateperone, Schizophrenia, Second Generation Antipsychotic, Dopamine Modulation, Serotonin Receptors
How to Cite?: J. Ben Samuel, Dr. S. Jebaseelan, "A Review Article on the Bioavailability of Lumateperone", Volume 15 Issue 6, June 2026, International Journal of Science and Research (IJSR), Pages: 1112-1112, https://www.ijsr.net/getabstract.php?paperid=SR26618191859, DOI: https://dx.doi.org/10.21275/SR26618191859